|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 09, 2018 ) Middle East and Africa Ulcerative Colitis Market was worth USD 0.41 billion in 2017 and is projected to grow at a CAGR of 6.7%, to reach USD 0.57 billion by 2022. Ulcerative Colitis is an inflammatory bowel disease that results in ulcers and inflammation of the rectum and colon. The disease usually lasts long term and the symptoms include diarrhea with blood and abdominal pain. It can also result in inflammations in several body parts and can also lead to colon cancer.
Browse For Full Report @ https://www.marketdataforecast.com/market-reports/middle-east-and-africa-ulcerative-colitis-market-6448/
The causes for the disease include genetics, dysfunction of immune system and some other factors. Endoscopy through the rectum is one of the best diagnostic options for ulcerative colitis. There are numerous medications available for the disease ranging from drugs to surgery. The risk of fatalities in patients with the disease is very low.
Request Sample Report @ https://www.marketdataforecast.com/market-reports/middle-east-and-africa-ulcerative-colitis-market-6448/request-sample
Due to the changing lifestyles of people with unhealthy diets, prevalence of ulcerative colitis has increased. Increase in investments in pharmaceutical industries for the development of novel drugs, growing risk of acquiring colon cancer and growing healthcare expenditure are expected to propel the market growth. However, strict regulations on product approvals especially biosimilars and chances of recurrence of the disease are hindering the market growth.
Inquire Before Buy @ https://www.marketdataforecast.com/market-reports/middle-east-and-africa-ulcerative-colitis-market-6448/inquire
The Ulcerative Colitis market is segmented by product, type, route of administration and region. By product, the market is categorized into Monoclonal Antibodies, Biosimilars and Pharmaceuticals. Biosimilars hold the largest market share due to their high production in the last decade due to the patent expiration of branded drugs. Monoclonal antibodies segment is the fastest growing segment due to their effectiveness at curing the disease. By type, the market is categorized into Proctosigmoiditis, Ulcerative Proctitis, Pancolitis and Left sided Colitis. Proctosigmoiditis is the most common type of ulcerative colitis and hence it holds the major market share. By route of administration, the market is categorized into Oral and Injectable products.
On the basis of region, the Ulcerative Colitis market is analyzed under Middle East and Africa regions. Middle East region lead the market due to the availability of better healthcare facilities. Due to the political unrest in both the regions, the market growth is slow and expansions become challenging.
Buy Now @ https://www.marketdataforecast.com/cart/buy-now/middle-east-and-africa-ulcerative-colitis-market-6448
Some of the major players in Ulcerative Colitis market are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche and Shire Pharmaceuticals.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Market Data Forecast.
Abhishek Shukla
18887029626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
